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 Decision making with D-dimer in the investigation of pulmonary embolism 
Measurement of a D-dimer level can be a powerful tool in the diagnosis of venous 
thromboembolism in the right context and with the right application. In conjunction with estimation 
of pre-test probability of venous thromboembolism, a D-dimer level can be used to risk stratify 
patients presenting with clinical features of venous thromboembolism such as pulmonary embolism. 
Used correctly, a clinical strategy combining pre-test probability estimation and D-dimer 
measurement can allow safe discharge of patients with suspected pulmonary embolism without 
superfluous investigation or unnecessary interim treatment. 
Where does D-dimer come from? 
Fibrinolysis is a tightly regulated and necessary mechanism to control thrombus propagation and 
maintain blood fluidity. The activation of coagulation by tissue injury and inflammation results in the 
deposition of fibrin-containing thrombus, and to avoid excessive thrombus and to allow thrombus to 
be remodelled and cleared as tissues heal, cross-linked fibrin is broken down by plasmin.1 This 
fibrinolysis results in the release of so-called fibrin degradation products into the circulation. The 
smallest of these degradation products, D-dimer, is routinely measured in clinical practice as a proxy 
marker of activation of fibrinolysis.2 Fibrinolysis is activated as thrombus is formed, so the D-dimer 
thereby becomes clinically useful to identify patients in whom pathological intravascular thrombus 
might be accumulating.  
Given that inflammation can activate the coagulation pathway through cytokine-mediated 
upregulation of endothelial cell surface tissue factor expression,3 D-dimer can also be considered a 
surrogate inflammatory marker. As such, an elevated D-dimer laboratory test cannot be considered 
a specific marker of venous thromboembolism, but its sensitivity makes it an asset in the diagnosis 
of venous thromboembolism such as pulmonary embolism where the pre-test probability of venous 
thromboembolism has been appropriately assessed.4 
D-dimer as a diagnostic test for pulmonary embolism 
The contemporary clinical use of D-dimer in the investigation of pulmonary embolism can probably 
be attributed to the efforts of Philip Wells and colleagues. Wells’ work with combining a clinical 
scoring algorithm and the laboratory D-dimer test to estimate the probability of pulmonary 
embolism was borne of the limitations of ventilation-perfusion lung scanning, which was the 
practical diagnostic standard for pulmonary embolism at the turn of the 21st century.5 Ventilation-
perfusion scans were occasionally non-diagnostic for pulmonary embolism, and if clinical suspicion 
for pulmonary embolism was high despite a non-diagnostic ventilation-perfusion scan and equivocal 
lower limb ultrasound for deep venous thrombosis, patients would sometimes subsequently be 
subjected to invasive pulmonary angiography and its associated risks.6 
The increasing utility of computed tomography pulmonary angiography in the intervening decade 
made the question of which patients to recommend for invasive angiography less relevant, but the 
use of ionising radiation and intravascular contrast media to confirm the diagnosis with computed 
tomography means that estimation of probability of pulmonary embolism before deciding whether 
to request computed tomography remains imperative. To this end the work of Wells and others is 
highly relevant, although several authors report inadequate estimation of probability of pulmonary 
embolism prior to computed tomography resulting in an overuse of computed tomography.7–9 
The utility of the D-dimer in the diagnosis of pulmonary embolism is maximised when the pre-test 
probability of pulmonary embolism is estimated. The Wells score emerged from a study of 
consecutive adult inpatients and outpatients with suspected pulmonary embolism with the aim of 
simplifying the estimation of pre-test probability (Table 1). Using prior observations of the varying 
likelihood of pulmonary embolism diagnosis with particular clinical features, Wells et al. constructed 
a clinical model that was first used to justify withholding anticoagulation where ventilation-perfusion 
scanning had proved inconclusive but pre-test probability had been low, and then later to justify 
ruling out pulmonary embolism where pre-test probability was acceptably low and D-dimer was 
negative.10,11 
As well as identifying features strongly associated with pulmonary embolism (such as tachycardia, 
haemoptysis and clinical features of lower limb venous thromboembolism), part of the assessment 
of pre-test probability of pulmonary embolism typically includes a clinician’s subjective assessment 
as to whether the clinical features identified in the patient are most likely to be attributed to 
pulmonary embolism. Wells and colleagues’ work to derive a clinical decision rule for diagnosis of 
pulmonary embolism suggested that where a clinician felt the observed clinical features were 
unlikely to be explained by a different diagnosis, the likelihood of subsequent confirmation of 
pulmonary embolism was increased four- to sixfold.11 (This is the basis of “alternative diagnosis less 
likely than pulmonary embolism” carrying 3 points on the Wells score for pulmonary embolism.) 
A clinical conundrum in the medical assessment unit can arise when a patient is assessed with 
knowledge of the D-dimer result, as can sometimes happen when blood tests are ordered before 
clinical assessment in the emergency department in an attempt to improve patient flow.12 Prior 
knowledge of the laboratory result can influence the clinician’s subjective assessment of whether an 
alternative diagnosis is less likely than pulmonary embolism and may therefore result in computed 
tomography scanning and/or anticoagulation where pulmonary embolism is unlikely, or no attempt 
to confirm a diagnosis of pulmonary embolism where it might be likely.13–15 It is possible, then, that 
strategies to minimise this bias might reduce patient harms caused by inappropriate investigation or 
treatment. 
Negative D-dimer at point of assessment 
Although the D-dimer assays in common use are sensitive for the detection of intravascular 
thrombus formation (a systematic review by Di Nisio et al. suggests 95% sensitivity of microplate 
enzyme-linked immunosorbent D-dimer assays for the detection of PE), a negative D-dimer does not 
necessarily rule out pulmonary embolism on its own.16 Wells and colleagues’ retrospective analysis 
of a cohort of almost 1000 patients investigated for pulmonary embolism suggested a 3% rate of 
pulmonary embolism in those with a negative D-dimer regardless of pre-test probability. In the 
subgroup of patients in whom the pre-test probability of pulmonary embolism was deemed high 
(Wells score >4) but D-dimer was negative, the rate of pulmonary embolism was 16%.11 Gibson et al. 
demonstrated a similar false-negative rate: a 2% rate of pulmonary embolism was observed in all 
patients suspected of pulmonary embolism with a negative D-dimer, and this rose to 9% in the 
subgroup with Wells score >4 and negative D-dimer.13 
Given the potentially grave consequences of missing a pulmonary embolism diagnosis having been 
reassured by a negative D-dimer result, a clinician assessing a patient for suspected pulmonary 
embolism where the D-dimer is already known to be negative should ensure that an attempt at pre-
test probability scoring is made using a clinical decision rule such as the Wells score. A score that 
suggests a high likelihood of pulmonary embolism should always prompt further investigation 
regardless of the D-dimer result. On the other hand, a Wells score that suggests a low likelihood of 
pulmonary embolism (less than or equal to 4) in conjunction with a negative D-dimer was associated 
with a 2% rate of pulmonary embolism in Wells’ original derivation cohort, but a later meta-analysis 
of prospective studies suggested a pooled incidence of pulmonary embolism of 0.34% in such 
populations.11,17 This would probably give most clinicians reassurance that pulmonary embolism had 
been ruled out. 
Positive D-dimer at point of assessment 
As above, the approach to the assessment of a patient with suspected pulmonary embolism known 
to have a positive D-dimer should begin with an estimation of the pre-test probability of pulmonary 
embolism, ideally using a clinical decision rule. However, given that three points of the Wells score 
hinge on the clinician’s subjective assessment of whether pulmonary embolism is the most likely 
explanation of the clinical observations, it is possible that knowledge of a positive D-dimer result 
could bias the clinician in favour of pulmonary embolism. This could lead to unnecessary subsequent 
investigation or even treatment with anticoagulation in an effort to keep the patient “safe” until 
diagnostic imaging can be performed. 
A questionnaire-based study undertaken in the Netherlands found that when physicians were 
presented with hypothetical cases with high diagnostic uncertainty for pulmonary embolism, the 
inclusion of an abnormal D-dimer result in the clinical information increased the probability of a 
clinician assigning a Wells score greater than 4 (which is the cut-off for “pulmonary embolism likely” 
on the two-level Wells score).18 A strategy to combat this bias might be to avoid looking at a D-dimer 
result before the clinical assessment if the temptation can be resisted, but the success of such a 
technique might depend upon the limitations of human nature. A more acceptable strategy might be 
to estimate the pre-test probability of pulmonary embolism retrospectively using a clinical decision 
rule that does not incorporate a subjective aspect, such as the revised Geneva score (Table 2).19 
Using the revised Geneva score, a score of 0-3 indicates a low clinical probability of pulmonary 
embolism, and in the original validation data this corresponded with a 7.9% prevalence of 
pulmonary embolism (95% confidence interval 5.0-12.1%).19 In this low probability group an 
elevated D-dimer is likely to be a false positive result, given the poor specificity of commonly used D-
dimer assays for pulmonary embolism.16 Scores of 4 and above, however, should warrant further 
investigation where a D-dimer result is already known to be positive. 
Meta-analyses have suggested that the Wells score stratifies pre-test probability of pulmonary 
embolism with similar accuracy to the revised Geneva score20,21 although there has not yet been a 
comparison of the two clinical decision scores in scenarios where the clinician has prior knowledge 
of the D-dimer result. As such, it is difficult to know whether using the revised Geneva score rather 
than the Wells score would truly eliminate the potential bias introduced by knowledge of the D-
dimer result prior to clinical assessment. 
Age-adjusted D-dimer 
The concept of “inflamm-aging” was borne of the observation that increasing age is associated with 
increasing levels of chronic low-grade systemic inflammation due to dysregulated immune 
responses.22 With increasing levels of systemic inflammation higher levels of soluble inflammatory 
markers can be measured in the blood, and it has also been demonstrated that higher baseline 
levels of D-dimer can be measured with increasing age.23,24 This may reflect the ability of D-dimer to 
act as a proxy inflammatory marker as discussed previously in this article. 
Given apparently higher baseline levels of D-dimer with age, the clinical utility of a fixed upper limit 
of normal (traditionally 500μg/L) has been called into question. Previous studies have suggested a 
reduction in the specificity of D-dimer for venous thromboembolism detection in older patients 
using a fixed cut-off value, and a recovery of specificity without loss of sensitivity by increasing the 
cut-off value with age.23,25 By retrospectively analysing previous data from cohort studies evaluating 
the diagnosis of pulmonary embolism, Douma et al. postulated that in patients older than 50, the 
clinical utility of the D-dimer test to detect pulmonary embolism increased if the cut-off was taken to 
be (age×10)μg/L.25 
Following this work, a prospective study was undertaken to assess the utility and safety of an age-
adjusted cut-off value for D-dimer in the diagnosis of pulmonary embolism. The ADJUST-PE study 
was a multicentre study of 3324 patients with suspected pulmonary embolism from hospitals in 
Belgium, France, the Netherlands and Switzerland in which the primary outcome measure was the 
failure rate of a diagnostic strategy using a clinical decision rule and a D-dimer cut-off value of 
(age×10)μg/L in patients older than 50. Patients younger than 50 years of age were evaluated using 
the traditional cut-off of 500μg/L. Although the study was not designed to compare the new strategy 
against usual practice directly, the failure rates of the new strategy were acceptably low, suggesting 
it to be safe. In addition, the age-adjusted D-dimer proved particularly useful in ruling out pulmonary 
embolism in patients aged 75 or older without further investigation: it was suggested that where 1 in 
16 patients would have had PE ruled out using the 500μg/L cut-off, this increased to 1 in 3.4 using 
the age-adjusted cut-off.26 This would indicate potential for cost savings by adopting the use of age-
adjusted cut-offs. 
Limitations of the use of D-dimer in pulmonary embolism diagnosis 
Even aside from the relative lack of specificity of D-dimer as discussed above, diagnosis of pulmonary 
embolism using D-dimer remains liable to pitfalls. Pregnant women have been notable absentees 
from the studies that inform contemporary strategies to diagnose pulmonary embolism. This is 
despite pregnancy conferring a seven- to tenfold increase in the risk of venous thromboembolism 
compared to age-matched controls.27 The use of D-dimer to aid pulmonary embolism diagnosis in 
pregnant women is not typically recommended in part due to observations of rising baseline levels 
of D-dimer in pregnant women over the course of pregnancy, which might reduce the specificity of a 
fixed threshold value for pulmonary embolism detection.28 In any case, there remains a dearth of 
prospective studies aimed at formulating a clinical decision strategy for pulmonary embolism 
diagnosis in pregnant women. 
The DiPEP study was a prospective cohort study of 324 pregnant and postpartum women in the 
United Kingdom that attempted to assess whether clinical features or D-dimer (alone or in 
combination) could be used to rule out pulmonary embolism without further diagnostic imaging. 198 
cases of confirmed pulmonary embolism were also analysed retrospectively to enable more precise 
estimates of sensitivity. The investigators found that existing clinical decision rules for pulmonary 
embolism were poor indicators of which patients were subsequently diagnosed with pulmonary 
embolism, and D-dimer thresholds (whether fixed at 500μg/L or adjusted for trimester) did not have 
sufficient discriminatory value for the test to be useful in diagnosis.29 For the gestation-adjusted D-
dimer thresholds, the DiPEP investigators used three discrete D-dimer threshold values—a threshold 
for each trimester—rather than the construction of a threshold varying continuously with 
gestational age as in the ADJUST-PE study. This might have cost the D-dimer some of its value as a 
diagnostic tool in this study, although it may well be that D-dimer simply has no diagnostic value for 
pulmonary embolism detection in pregnancy. 
In considering the value of D-dimer to exclude venous thromboembolism, causes of false-normal D-
dimer should also be considered. A readily apparent cause is concurrent use of anticoagulation, 
which would reduce the chance of fibrin being formed by the coagulation cascade and would 
therefore result in the observation of fewer degradation products from fibrinolysis.1 
Advances in biomarkers for venous thromboembolism 
Given the low specificity of the D-dimer test for venous thromboembolism detection, the 
diagnostician’s dream would probably be the development of a new test that would quickly return a 
positive result in every case of venous thromboembolism without a risk of false positives. Although 
that remains far-fetched at present, research taking advantage of high-throughput proteomics may 
be able to offer some hope of improving upon current laboratory tests for venous 
thromboembolism. 
By analysing the protein contents of blood samples from recently-diagnosed venous 
thromboembolism patients and controls, the investigators of the VEREMA study were able to 
identify strong associations between venous thromboembolism and plasma levels of four proteins: 
human immunodeficiency virus type I enhancer binding protein 1, von Willebrand factor and 
platelet-derived growth factor β. The associations of von Willebrand factor and platelet-derived 
growth factor β with venous thromboembolism were observed once more when the investigators 
replicated the findings by profiling an external biobank, leading to the conclusion that platelet-
derived growth factor β could have merit as a biomarker for venous thromboembolism risk.30 
Menon et al. used similar techniques to identify plasma proteins strongly associated with the 
diagnosis of venous thromboembolism and then attempted to assess the diagnostic potential of 
combinations of these proteins in the detection of venous thromboembolism. A combination of 
activated protein C-protein C inhibitor and osteopontin demonstrated comparable sensitivity to D-
dimer and higher specificity when tested retrospectively on blood samples from patients diagnosed 
with venous thromboembolism and controls.31 
Despite showing promise, experimental correlations between venous thromboembolism and 
elevated levels of plasma proteins might not be sufficient to supplant established laboratory tests 
such as D-dimer without further investigation. Nevertheless, such work suggests that improvements 
on currently available diagnostics may be on the horizon. 
Conclusions 
D-dimer, despite its flaws, remains a valuable tool in the diagnosis of venous thromboembolism. 
Although it may be increasingly common to have a D-dimer result available before clinical 
assessment, that should not preclude a structured approach to pulmonary embolism diagnosis, and 
considered use of available information should minimise the number of patients inappropriately 
investigated or treated. Further work remains to be done on eliminating diagnostic error arising 
from knowledge of the D-dimer result prior to clinical assessment, and future work should also 
attempt to clarify the uncertain role of D-dimer in venous thromboembolism diagnosis in pregnancy. 
It remains to be seen whether recent developments in high-throughput proteomics can result in 
biomarkers that might supplant D-dimer in the diagnosis of venous thromboembolism. 
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Variable Points 
Clinical signs and symptoms of deep vein thrombosis 3.0 
Immobilisation or surgery in previous 4 weeks 1.5 
Heart rate greater than 100 beats/min 1.5 
Previous history of pulmonary embolism or deep vein thrombosis 1.5 
Haemoptysis 1.0 
Malignancy 1.0 
Alternative diagnosis is less likely than pulmonary embolism 3.0 
Table 1. 2-level Wells score.11 If score ≤4 pulmonary embolism unlikely; if score >4 pulmonary embolism 
likely 
 Variable Points 
Age >65 1 
Previous deep vein thrombosis or pulmonary embolism 3 
Surgery (under general anaesthesia) or fracture (of the lower limbs) within 1 month 2 
Active malignant condition (solid or haematologic malignant condition, currently 
active or considered cured <1 year) 
2 
Unilateral lower limb pain 3 
Haemoptysis 2 
Heart rate 75-94 beats/minute 3 
Heart rate ≥95 beats/minute 5 
Pain on lower limb deep venous palpation and unilateral oedema 4 
Table 2. Revised Geneva score.18 Score 0-3 low probability; score 4-10 intermediate; score ≥11 high 
